Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 535

Results For "US"

8107 News Found

Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules
Drug Approval | December 20, 2022

Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules

According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million


Guerison to set up footprints in India’s ophthalmology market
News | December 20, 2022

Guerison to set up footprints in India’s ophthalmology market

Global pharmaceutical company having a surgical business concept incepted in Dubai


Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer
Drug Approval | December 20, 2022

Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer

This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting


Cadila Pharmaceuticals appoints Ashraf Allam as Global COO
People | December 20, 2022

Cadila Pharmaceuticals appoints Ashraf Allam as Global COO

Allam was serving recently as the CEO at Public Investment Fund


Ipca acquires further 6.53% of equity share of Trophic Wellness
News | December 20, 2022

Ipca acquires further 6.53% of equity share of Trophic Wellness

Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.


Emcure conducts oral and health check-up camps for students in Pune
Healthcare | December 20, 2022

Emcure conducts oral and health check-up camps for students in Pune

The camps were organised along with the doctors from Bharti Vidyapeeth Dental College and Hospital, Katraj, Pune, and Emcure’s occupational health centre (OHC) doctors


Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData
Healthcare | December 20, 2022

Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData

36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.